ReviewFrontiers in oncology2026
Is leptomeningeal dissemination in oligodendroglioma predictable? Evidence from a scoping review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oligodendrogliomas (ODGs) are IDH-mutated gliomas with 1p/19q co-deletion, typically associated with better outcomes than astrocytomas. Symptomatic leptomeningeal dissemination (LMD) is exceptionally rare, and predictors of its occurrence remain poorly defined. This scoping review aimed to synthesize the available literature on LMD in ODG and identify potential clinical, radiological, surgical, and histo-molecular risk markers. Methods: PubMed/MEDLINE and Embase were systematically searched for studies reporting cases of ODG with LMD. Extracted data included demographics, tumor features, imaging, treatment, molecular markers, and outcomes. Findings were descriptively summarized. An illustrative institutional case was also reviewed. Results: Of 1719 records screened, 15 studies met inclusion, comprising 48 patients. The mean age at LMD diagnosis was 43.1 years, with male predominance (M: F = 2.4:1). Most patients (39 of 41 patients [85.7%]) had WHO grade 3 ODG at LMD diagnosis. When explicitly stated, LMD was associated with surgical entry into the ventricles (2 of 4 patients [50%]), a Ki-67 index of ≥15% (6 of 7 patients [85.7%]), and contrast enhancement on MRI (4 of 8 patients [75%]). The median time from ODG diagnosis to LMD was 35 months (range 0-274 months). Median survival after LMD was 9.9 months (range 1.8-67.7). Our case reflected these patterns, with 14 years of stable disease followed by rapid decline after LMD onset. Treatments included chemotherapy (23 of 39 patients [58.9%]), radiotherapy (14 of 39 patients [35.9%]), and surgery (12 of 40 patients [30%]), with uncertain benefit. Discussion: LMD in ODG is rare but associated with poor prognosis. Features such as grade 3 histology, ventricular involvement, surgical entry into ventricles, contrast enhancement, and high Ki-67 may indicate potential risk markers. These findings support long-term whole-neuroaxis MRI surveillance in selected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.